Bavarian Nordic maintains guidance for 2021

In its Thursday Q1 report, Bavarian Nordic states that it is maintaining its guidance for 2021. It expects DKK 1.9-2.2bn in revenue and an operating result of DKK 100-250m.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Bavarian Nordic closed its first quarter with growth on the top line though negative results in operations and on the bottom line have also increased significantly.

The company is advancing in spite of waning sales from the vaccines Rabipur/Rabavert for rabies and Encepur for tick-borne encephalitis.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs